At AAIC, researchers will present updates on Roche’s trontinemab, an anti-amyloid drug designed to enter the brain more efficiently with fewer side effects and Biogen’s diranersen, a tau-silencing drug that stops the spread of toxic tau tangles. More data is being presented about Novo Nordisk’s GLP-1 semaglutide, which failed to slow cognitive decline.